NeonMind Biosciences Inc.
NMDBF · OTC
11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $416 | – |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | – |
| Gross Profit | $0 | $0 | $416 | – |
| % Margin | – | – | 99.9% | – |
| R&D Expenses | $149 | $1,356 | $270 | – |
| G&A Expenses | $1,281 | $4,633 | $1,530 | – |
| SG&A Expenses | $1,601 | $6,419 | $1,715 | – |
| Sales & Mktg Exp. | $320 | $1,787 | $185 | – |
| Other Operating Expenses | $0 | $0 | $0 | – |
| Operating Expenses | $1,751 | $7,776 | $1,988 | – |
| Operating Income | -$1,751 | -$7,776 | -$1,622 | – |
| % Margin | – | – | -390.1% | – |
| Other Income/Exp. Net | -$283 | $1,092 | -$1,078 | – |
| Pre-Tax Income | -$2,034 | -$6,684 | -$2,677 | – |
| Tax Expense | $0 | $557 | $0 | – |
| Net Income | -$2,034 | -$7,208 | -$2,677 | – |
| % Margin | – | – | -643.8% | – |
| EPS | -53.93 | -7.33 | -2.86 | – |
| % Growth | -635.7% | -156.3% | – | – |
| EPS Diluted | -53.93 | -7.33 | -2.86 | – |
| Weighted Avg Shares Out | 38 | 983 | 937 | – |
| Weighted Avg Shares Out Dil | 38 | 983 | 937 | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | – |
| Interest Expense | $280 | $33 | $26 | – |
| Depreciation & Amortization | $1 | $1 | $4 | – |
| EBITDA | -$1,474 | -$6,617 | -$2,670 | – |
| % Margin | – | – | -642.1% | – |